Literature DB >> 7716081

Immunohistochemical localization of cathepsin B in neoplastic human prostate.

A A Sinha1, M J Wilson, D F Gleason, P K Reddy, M Sameni, B F Sloane.   

Abstract

Cathepsin B (CB) has been shown to degrade extracellular matrix (ECM) proteins, and has been reported to be involved in invasion and metastasis of several types of solid organ tumors in human and animals, but CB has not been studied in human prostate cancer (CAP). Our objective was to determine the CB protein immunostaining pattern in CAP and to correlate the immunostaining with the degree of malignancy as reflected in the Gleason grading system. We used two types of CB antibodies (namely, monospecific, polyclonal antibodies to human liver CB prepared in rabbits, and polyclonal antibody produced in sheep) to establish CB localization patterns in neoplastic prostate. Our analysis showed a heterogeneous CB immunostaining pattern in the neoplastic human prostate. CB immunostaining occurred in many, but not all, of the neoplastic columnar/cuboidal cells of acini and isolated cells, i.e., in small ragged glands and clusters (groups) of invasive cells in the prostatic stroma. We have shown that, in general, there was a positive correlation of the intensity of CB immunostaining with the Gleason histologic score (or Gleason grade sum) tumors, i.e., from the lowest scores through score 8, but many of the tumors with scores 9 and 10 showed little CB immunostaining. Our study indicated that the increased CB immunostaining in the Gleason grade sum 5-8 tumors may be associated with increased degradation of ECM, but not in 9 and 10 despite the fact that the latter tumors are more malignant clinically. In well-differentiated tumors, fewer CB immunostaining cells were present than the moderately-differentiated tumors. In other words, most of the stromal invasion of the prostatic ECM occurred in tumors of Gleason grade sums 5-8. We suggest that CB immunostaining might be a useful method to assess stromal invasion of prostatic carcinoma, especially in the higher grade tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7716081     DOI: 10.1002/pros.2990260402

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  12 in total

1.  Zinc finger E-box binding homeobox-1 (Zeb1) drives anterograde lysosome trafficking and tumor cell invasion via upregulation of Na+/H+ Exchanger-1 (NHE1).

Authors:  Samantha S Dykes; ChongFeng Gao; William K Songock; Rebecca L Bigelow; George Vande Woude; Jason M Bodily; James A Cardelli
Journal:  Mol Carcinog       Date:  2016-08-22       Impact factor: 4.784

2.  Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.

Authors:  Izabela Podgorski; Bruce E Linebaugh; Mansoureh Sameni; Christopher Jedeszko; Sunita Bhagat; Michael L Cher; Bonnie F Sloane
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

3.  Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.

Authors:  S R Denmeade; W Lou; J Lövgren; J Malm; H Lilja; J T Isaacs
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

4.  Cathepsin B and D are Localized at the Surface of Human Breast Cancer Cells.

Authors:  Mansoureh Sameni; Edith Elliott; Grace Ziegler; Philip H Fortgens; Clive Dennison; Bonnie F Sloane
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

5.  The metastatic potential of human pancreatic cell lines in the liver of nude mice correlates well with cathepsin B activity.

Authors:  George N Tzanakakis; Andrew N Margioris; Aristidis M Tsatsakis; Michael P Vezeridis
Journal:  Int J Gastrointest Cancer       Date:  2003

6.  Cathepsin B and Cathepsin D Expression in Follicular Adenomas and Carcinomas of the Thyroid Gland.

Authors:  Steven M. Ruhoy; Martha R. Clarke
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

7.  Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents.

Authors:  Victoria Smith; Gregory J Wirth; Heinz-Herbert Fiebig; Angelika M Burger
Journal:  Cancer Genomics Proteomics       Date:  2008 Sep-Oct       Impact factor: 4.069

8.  A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma.

Authors:  S J Hughes; T W Glover; X X Zhu; R Kuick; D Thoraval; M B Orringer; D G Beer; S Hanash
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

Review 9.  Nanotheranostics for personalized medicine.

Authors:  Tae Hyung Kim; Seulki Lee; Xiaoyuan Chen
Journal:  Expert Rev Mol Diagn       Date:  2013-04       Impact factor: 5.225

10.  Protease-activated drug development.

Authors:  Ki Young Choi; Magdalena Swierczewska; Seulki Lee; Xiaoyuan Chen
Journal:  Theranostics       Date:  2012-02-08       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.